Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.
about
Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implicationsCross-platform analysis of cancer microarray data improves gene expression based classification of phenotypesMidostaurin: an emerging treatment for acute myeloid leukemia patientsMolecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapyMolecular prognostic factors in cytogenetically normal acute myeloid leukemiaProgress in acute myeloid leukemiaFLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyGene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Le'Acute myeloid leukemia: a comprehensive review and 2016 update'Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitationsClinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewThe FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactionsMll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemiasFuture prospects of therapeutic clinical trials in acute myeloid leukemia.Prognostic significance of FLT3-ITD in pediatric acute myeloid leukemia: a meta-analysis of cohort studies.Platelet factor-4 is an indicator of blood count recovery in acute myeloid leukemia patients in complete remission.Specific pattern of protein expression in acute myeloid leukemia harboring FLT3-ITD mutations.Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignanciesCopy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AMLFunctional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITDLong FLT3 internal tandem duplications and reduced PML-RARĪ± expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemiaGenomic imbalances are confined to non-proliferating cells in paediatric patients with acute myeloid leukaemia and a normal or incomplete karyotype.Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemiaTreatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.Long-term follow-up of cytogenetically normal CEBPA-mutated AMLImpact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia.Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyClinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm
P2860
Q24617091-A08CCCA6-A1BA-4448-B21C-5A0B8964825AQ24811346-3B06A187-D490-46EB-9E7A-26A9D4DFD9DCQ26749271-9046D3BC-BAC6-4DA7-8AFC-375114220451Q26749870-9B6A84FF-EDC4-4190-A701-018C53EF57AFQ26998811-6A5BD17F-48A1-48D6-967B-146E2EDB8F45Q27024006-AB0BB143-1B85-4C1D-9FFA-2D5C094E6AC5Q27028163-8EB6B7F5-52DD-4456-84F6-FD7F44765B23Q27851415-F58E832C-3147-4A3E-AA64-0DF85693758CQ27851436-B3531124-13FF-479A-9076-549CCA872155Q27851460-7371F385-E273-4696-90C3-88768DD2CC14Q27851726-59B5F401-1F40-4CE0-AC73-E264BA403469Q27853031-0FAD6609-BE7F-486D-A76F-498920A78665Q28072539-C32FE690-50E9-4D7C-BADC-250294C1A511Q28081844-4E91B551-1C8A-466C-B03C-649EF31D7AC5Q28289859-7794E02E-B93B-4DBB-93E7-AAE1D2415883Q28301344-2F015E6A-1591-4675-BEEA-E0F2E348A43CQ28535342-F5C54E7C-075E-423B-8C7A-9A0C20541AE8Q28594733-EFFE7940-9105-491D-932D-80CDADD34145Q30244168-32F39028-F72F-424F-8AD6-D4D61276076DQ30248904-E6DA94A1-C1DA-4BEF-B95C-84D30CEFA7B0Q30838366-4A7B5116-C5B2-46A7-9DBB-D6039BE69012Q33309313-60DB82DF-4FBF-4237-978B-37683668EA09Q33437478-9AD92B65-53D4-49D0-B9BC-6F8A7F4863E7Q33702150-7E900C70-3AE4-4EA6-8E1F-A1DCB1EE9635Q33737486-861BA4BA-994D-4FCB-9172-1AB628312344Q33798909-4379B37E-1C1C-4D43-99D6-74AD1BBF3CBCQ33829079-F55AEAA7-BE56-45F5-8FE1-227FF26E2984Q33871210-29AB68AD-342F-4868-B54E-1AD9DCCECB94Q33913329-8A90741E-A9DC-416C-B547-B5512573ED4EQ33939071-1D3E2B50-1B4C-468C-92FC-404AD26EEE7AQ34004131-6FD020F7-BC12-42A6-90F9-A51219314D77Q34011740-706DDFEB-23FF-4FFF-BE4C-A9637BFE881EQ34095013-E4B3BE37-B7B4-4F2B-BA8A-3374D8C103AEQ34176732-4263933C-DDD3-49FD-AC83-44E50E3CAF7DQ34233639-310968EE-C27A-400D-ABA5-67087795493CQ34285896-C1589016-BF22-4F08-94CE-1D1341EA96DCQ34285937-C2534621-056E-46D0-A978-ED7BAC0EF1F1Q34310561-71FF2AA0-99EF-4DB8-8312-865665EAB220Q34340438-7B6FCA20-3BD9-4AEE-85E4-894DBEEC38E8Q34408941-B4B35E50-041F-48FB-BC7E-B49B04776468
P2860
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.
description
2002 nĆ® lÅ«n-bĆ»n
@nan
2002幓ć®č«ę
@ja
2002幓å¦ęÆęē«
@wuu
2002幓å¦ęÆęē«
@zh
2002幓å¦ęÆęē«
@zh-cn
2002幓å¦ęÆęē«
@zh-hans
2002幓å¦ęÆęē«
@zh-my
2002幓å¦ęÆęē«
@zh-sg
2002幓åøč”ęē«
@yue
2002幓åøč”ęē«
@zh-hant
name
Prognostic significance of act ...... dy of the AML Study Group Ulm.
@en
Prognostic significance of activating FLT3 mutations in younger adults
@nl
type
label
Prognostic significance of act ...... dy of the AML Study Group Ulm.
@en
Prognostic significance of activating FLT3 mutations in younger adults
@nl
prefLabel
Prognostic significance of act ...... dy of the AML Study Group Ulm.
@en
Prognostic significance of activating FLT3 mutations in younger adults
@nl
P2093
P1433
P1476
Prognostic significance of act ...... dy of the AML Study Group Ulm.
@en
P2093
AML Study Group Ulm. Acute myeloid leukemia
Axel Benner
Jochen Breitruck
Karen Tobis
Richard F Schlenk
Stefan Frƶhling
Sylvia Kreitmeier
P304
P356
10.1182/BLOOD-2002-05-1440
P407
P577
2002-08-08T00:00:00Z